Plus Therapeutics regains Nasdaq compliance on two listing rules; bid price deadline extended to Nov 12, 2025

PLUS THERAPEUTICS, INC.

Nasdaq confirmed compliance with MVLS ($35M) and equity ($2.5M) standards on Aug 22, 2025.
Bid price rule deadline extended to Nov 12, 2025; prior Sept 8 deadline no longer applies.
One-year monitoring for equity standard through Aug 22, 2026; breach triggers delist process without cure period.
Company now satisfies two alternative criteria under Nasdaq Listing Rule 5550.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.